CONCORD BIOTECH
|
CONCORD BIOTECH Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 29.45 | 22.95 | 183.92 | 246.92 | 177.66 |
| CEPS(Rs) | 34.57 | 28.11 | 21.50 | 25.08 | 18.18 |
| DPS(Rs) | 8.75 | 6.83 | 51.20 | 74.15 | 6.00 |
| Book NAV/Share(Rs) | 145.93 | 123.31 | 1,159.94 | 1,050.75 | 809.87 |
| Tax Rate(%) | 25.32 | 25.44 | 26.35 | 24.89 | 20.86 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 42.50 | 40.86 | 37.73 | 52.14 | 39.14 |
| EBIT Margin(%) | 40.88 | 38.89 | 33.56 | 49.89 | 41.07 |
| Pre Tax Margin(%) | 40.57 | 37.74 | 32.72 | 49.72 | 40.85 |
| PAT Margin (%) | 30.30 | 28.14 | 24.10 | 37.35 | 32.33 |
| Cash Profit Margin (%) | 35.57 | 34.47 | 30.99 | 41.73 | 36.40 |
| Performance Ratios | |||||
| ROA(%) | 19.17 | 15.92 | 12.43 | 19.89 | 16.11 |
| ROE(%) | 21.88 | 20.06 | 16.64 | 26.55 | 21.94 |
| ROCE(%) | 29.13 | 26.70 | 21.66 | 32.96 | 26.23 |
| Asset Turnover(x) | 0.63 | 0.57 | 0.52 | 0.53 | 0.50 |
| Sales/Fixed Asset(x) | 1.25 | 1.13 | 1.06 | 1.31 | 1.68 |
| Working Capital/Sales(x) | 1.35 | 1.59 | 2.52 | 1.69 | 1.66 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.80 | 0.89 | 0.94 | 0.76 | 0.60 |
| Receivable days | 111.87 | 108.22 | 102.99 | 104.76 | 128.17 |
| Inventory Days | 75.42 | 87.15 | 87.67 | 76.85 | 77.69 |
| Payable days | 149.88 | 179.16 | 144.10 | 192.42 | 200.10 |
| Valuation Parameters | |||||
| PER(x) | 51.68 | - | - | - | - |
| PCE(x) | 44.02 | - | - | - | - |
| Price/Book(x) | 10.43 | - | - | - | - |
| Yield(%) | 0.57 | - | - | - | - |
| EV/Net Sales(x) | 15.62 | - | -0.03 | 0.06 | 0.11 |
| EV/Core EBITDA(x) | 34.08 | - | -0.06 | 0.10 | 0.23 |
| EV/EBIT(x) | 38.20 | -0.01 | -0.08 | 0.11 | 0.26 |
| EV/CE(x) | 10.36 | - | -0.01 | 0.03 | 0.05 |
| M Cap / Sales | 15.66 | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 19.20 | 19.67 | 15.56 | 20.42 | - |
| Core EBITDA Growth(%) | 21.38 | 29.11 | -12.99 | 44.86 | - |
| EBIT Growth(%) | 25.30 | 36.18 | -22.35 | 46.17 | - |
| PAT Growth(%) | 28.33 | 37.25 | -25.53 | 39.02 | - |
| EPS Growth(%) | 28.33 | -87.52 | -25.51 | 38.99 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.02 | 0.05 | 0.09 | 0.06 |
| Current Ratio(x) | 6.30 | 3.79 | 1.84 | 2.57 | 2.41 |
| Quick Ratio(x) | 4.84 | 2.69 | 1.27 | 1.92 | 1.91 |
| Interest Cover(x) | 130.57 | 33.85 | 39.72 | 299.68 | 183.92 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of CONCORD BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CONCORD BIOTECH | ₹21,098.3 Cr | 6.3% | -3% | 73.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹453,486.0 Cr | -0.6% | 1.3% | 65.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,321.0 Cr | -1.1% | 11.4% | 64% | Stock Analytics | |
| CIPLA | ₹125,852.0 Cr | -2.3% | -6.8% | 33.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,799.0 Cr | 1.5% | 1% | 22.9% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹102,726.0 Cr | -4.2% | -8.1% | 72.3% | Stock Analytics | |
CONCORD BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD BIOTECH | 6.3% |
-3% |
73.7% |
| SENSEX | -0.7% |
-2.4% |
22% |
You may also like the below Video Courses
